Abstract: PO0131
Humoral Response to the BNT162b2 Vaccine in Hemodialysis Patients
Session Information
- COVID-19: Vaccines, Diagnosis, and Treatment
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Yau, Kevin, University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
- Abe, Kento T., Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada
- Perl, Jeffrey, University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
- Naimark, David M., University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
- Chan, Christopher T., University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
- Oliver, Matthew J., University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
- Colwill, Karen, Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada
- Gingras, Anne-Claude, Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada
- Hladunewich, Michelle A., University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
Background
Hemodialysis (HD) patients have high mortality from COVID-19 and immunity following vaccination remains uncertain. This study evaluated SARS-CoV-2 antibody response in HD patients following BNT162b2 COVID-19 vaccination compared to health care workers (HCW) and convalescent serum.
Methods
This single centre observational cohort study enrolled 142 HD patients and 35 HCW receiving the BNT162b2 vaccine. SARS-CoV-2 IgG antibodies to the spike protein (anti-spike), receptor binding domain (anti-RBD), and nucleocapsid protein (anti-NP) were measured in 66 HD patients receiving one vaccine dose, 76 HD patients receiving two vaccine doses, and 35 HCW receiving two vaccine doses.
Results
In HD patients receiving a single BNT162b2 dose, seroconversion occurred in 53/66 (80%) for anti-spike and 35/66 (55%) for anti-RBD by 28 days post dose, but only 15/66 (23%) and 4/66 (6%), respectively attained a robust response defined as reaching the median level of anti-spike and anti-RBD in convalescent serum. In patients receiving two doses of BNT162b2 vaccine, seroconversion occurred in 69/72 (96%) for anti-spike and 63/72 (88%) for anti-RBD by 2 weeks following the second dose while 52/72 (72%) and 43/72 (60%) reached median convalescent serum levels of anti-spike and anti-RBD. In HCW, 35/35 (100%) exceeded median levels of anti-spike and anti-RBD in convalescent serum 2-4 weeks post second dose.
Conclusion
This study found poor immunogenicity 28 days following a single dose of BNT162b2 vaccine in HD patients, supporting adherence to recommended vaccination schedules, and avoiding delay of the second dose in this population.
Figure 1: SARS-CoV-2 IgG Spike, RBD, and NP Antibody Response Following One Versus Two Dose BNT162b2 Vaccine in Hemodialysis Patients.
Funding
- Government Support – Non-U.S.